Implication of CCR4-NOT Complex Subunit 7 Expression in Natural Killer Cell Resistance in Metastatic Breast Cancer - Trial NCT06320392
Access comprehensive clinical trial information for NCT06320392 through Pure Global AI's free database. This phase not specified trial is sponsored by Ain Shams University and is currently Recruitment Completed. The study focuses on Metastatic Breast Cancer. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
Ain Shams University
Timeline & Enrollment
N/A
Jul 01, 2021
Jun 01, 2024
Primary Outcome
Cytoplasmic mRNA deadenylase CNOT7 protein expression level in metastatic/advanced localized and non-metastatic BC sera using ELISA.,CNOT7 tissue expression level in BC tissue samples categorized as metastatic vs non-metastatic tumor alongside with adjacent non-tumor tissue margin using immunohistochemistry.,LAIR-1 protein expression level in BC patients peripheral blood samples using ELISA.
Summary
Being a mechanistic study, this work aims to figure out the role of the cytoplasmic mRNA
 deadenylase CNOT7 expressed protein on NK cell resistance in metastatic BC. In other words,
 to explore, whether, CNOT7 contributes to metastasis in Egyptian female metastatic BC
 patient's cohort, through NK cell resistance, or not.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06320392
Non-Device Trial